Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > The Promise of Tomorrow, A NanoTexas Radio Interview with Dr. Tamarkin

Abstract:
On Thursday, October 2, 2008, Dr. Tamarkin will be a featured speaker from 10:30-12:30 in the medicine and biology track at NanoTx08. His speech will focus on the recent Phase I CYT-6091 cancer patient trial in which the Company's gold nanomedicine was used to deliver a potent, but toxic, anti-cancer therapeutic to solid tumors. Such tumor targeting is best accomplished by avoiding uptake by the immune system and by limiting the biodistribution of the drug to the tumor. CYT-6091 accomplishes this by binding the potent, but toxic molecule TNF to the surface of PEGylated colloidal gold nanoparticles. TNF's toxicity is so severe that its clinical use is limited to isolated limb perfusion (ILP), where 1 mg of TNF followed by doxorubicin results in a 60-85% local response rate. In the completed CYT-6091 Phase I dose escalation clinical trial a similar dose of TNF was injected systemically. The treatment was well-tolerated, showing no dose limiting toxicity, and patient biopsies taken 24-hours after treatment showed gold nanoparticles in patient tumors. Multiple Phase II combination trials are planned.

The Promise of Tomorrow, A NanoTexas Radio Interview with Dr. Tamarkin

Rockville, MD | Posted on September 30th, 2008

####

About CytImmune Sciences, Inc.
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. Based on an R&D strategy which harnesses the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, the Company is developing a pipeline of proprietary drug candidates binding potent anti-cancer agents -- whose toxicity profiles currently prevent or severely limit clinical use -- to its patented colloidal gold tumor-targeting nanotechnology.

Leveraging its expertise in colloidal gold-based nanomedicines, CytImmune has also developed a patented, semi-synthetic in vitro immune system capable of producing fully-human monoclonal antibody (mAb) therapeutics. The Company’s ability to produce fully human mAbs provides an additional pathway to develop proprietary anti-cancer therapeutics using its platform technology to create a separate class of nanomedicines.

For more information, please click here

Contacts:
CytImmune Sciences
9640 Medical Center Drive
Rockville, MD 20850
Phone: (240)-864-2796
Fax: (301) 315-2438

Copyright © CytImmune Sciences, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Nanomedicine

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

Announcements

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Events/Classes

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

WITec to host the 11th Confocal Raman Imaging Symposium from September 29th - October 1st in Ulm, Germany July 28th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE